Processa Pharmaceuticals Files S-1/A Amendment
Ticker: PCSA · Form: S-1/A · Filed: Jan 16, 2025 · CIK: 1533743
| Field | Detail |
|---|---|
| Company | Processa Pharmaceuticals, Inc. (PCSA) |
| Form Type | S-1/A |
| Filed Date | Jan 16, 2025 |
| Risk Level | medium |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $0.851, $0.125, $0.0001, $20,000, $75,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, s-1a, pharmaceuticals
TL;DR
Processa Pharma (PRSA) filed an S-1/A, looks like they're still pushing for that public offering.
AI Summary
Processa Pharmaceuticals, Inc. filed an amendment (S-1/A) on January 16, 2025, for its registration statement. The company, formerly known as Heatwurx, Inc., is incorporated in Delaware and operates in the pharmaceutical preparations sector. Its principal executive offices are located at 7380 Coca Cola Drive, Suite 106, Hanover, Maryland.
Why It Matters
This filing indicates Processa Pharmaceuticals is moving forward with its public offering plans, which could lead to new investment opportunities and increased liquidity for its shares.
Risk Assessment
Risk Level: medium — S-1/A filings are typically associated with early-stage companies seeking capital, which inherently carries higher investment risk.
Key Numbers
- 333-283986 — SEC File Number (Identifies the specific registration filing.)
- 20250116 — Filing Date (Date the amendment was filed with the SEC.)
Key Players & Entities
- Processa Pharmaceuticals, Inc. (company) — Registrant
- 333-283986 (dollar_amount) — SEC File Number
- 20250116 (date) — Filing Date
- Heatwurx, Inc. (company) — Former Company Name
- George Ng (person) — Chief Executive Officer
FAQ
What is the purpose of this S-1/A filing?
This is an amendment to a Form S-1 Registration Statement, indicating Processa Pharmaceuticals, Inc. is updating information related to its public offering.
When was this amendment filed?
The amendment was filed as of January 16, 2025.
What was Processa Pharmaceuticals, Inc. formerly known as?
The company was formerly known as Heatwurx, Inc., with a name change date of October 28, 2011.
Where is Processa Pharmaceuticals, Inc. headquartered?
The company's principal executive offices are located at 7380 Coca Cola Drive, Suite 106, Hanover, Maryland 21076.
Who is the CEO of Processa Pharmaceuticals, Inc.?
George Ng is listed as the Chief Executive Officer.
Filing Stats: 4,481 words · 18 min read · ~15 pages · Grade level 16 · Accepted 2025-01-16 06:24:42
Key Financial Figures
- $0.851 — at an assumed public offering price of $0.851 per share (equal to the last sale price
- $0.125 — hare under Nasdaq rule 5635(d) plus (b) $0.125 per whole share of common stock underly
- $0.0001 — of common stock at an exercise price of $0.0001 per share of common stock. The public o
- $20,000 — -accountable expense allowance of up to $20,000 and will reimburse the placement agent
- $75,000 — fees and expenses in an amount of up to $75,000. For a description of compensation to b
Filing Documents
- forms-1a.htm (S-1/A) — 656KB
- ex4-2.htm (EX-4.2) — 121KB
- ex4-3.htm (EX-4.3) — 118KB
- ex5-1.htm (EX-5.1) — 21KB
- ex10-12.htm (EX-10.12) — 266KB
- ex10-13.htm (EX-10.13) — 66KB
- ex23-1.htm (EX-23.1) — 5KB
- ex107.htm (EX-FILING FEES) — 37KB
- forms-1_002.jpg (GRAPHIC) — 104KB
- ex5-1_001.jpg (GRAPHIC) — 20KB
- ex23-1_002.jpg (GRAPHIC) — 6KB
- 0001493152-25-002455.txt ( ) — 1470KB
Risk Factors
Risk Factors 9 Special Note Regarding Forward-Looking Statements 13
Use of Proceeds
Use of Proceeds 14 Dividend Policy 15 Capitalization 15
Executive Compensation
Executive Compensation 17 Beneficial Ownership 24
Description of Capital Stock
Description of Capital Stock 25
Description of Securities We Are Offering
Description of Securities We Are Offering 29 Material U.S. Federal Income Tax Consequences 31 Plan of Distribution 37 Legal Matters 39 Experts 39 Information Incorporated by Reference 39 Where You Can Find More Information 40 i ABOUT THIS PROSPECTUS You should rely only on the information we have provided or incorporated by reference into this prospectus, any applicable prospectus supplement and any related free writing prospectus. We incorporate by reference important information into this prospectus. You may obtain the information incorporated by reference without charge by following the instructions under “Where You Can Find More Information.” You should carefully read this prospectus as well as additional information described under “Incorporation of Certain Information By Reference,” before deciding to invest in our securities. We have not, and the placement agent and its affiliates have not, authorized anyone to provide you with any information or to make any representation not contained or incorporated by reference in this prospectus or any related free writing prospectus. We do not, and the placement agent and its affiliates do not, take any responsibility for, and can provide no assurance as to the reliability of, any information that others may provide to you. This prospectus is not an offer to sell or an offer to buy securities in any jurisdiction where offers and sales are not permitted. The information in this prospectus is accurate only as of its date, regardless of the time of delivery of this prospectus or any sale of securities. You should also read and consider the information in the documents to which we have referred you under the caption “Where You Can Find More Information” in the prospectus. To the extent there is a conflict between the information contained in this prospectus, on the one hand, and the information contained in any document incorporated by reference filed with the